1094 related articles for article (PubMed ID: 19758618)
1. Intravenous zoledronic acid to prevent osteoporosis in a veteran population with multiple risk factors for bone loss on androgen deprivation therapy.
Bhoopalam N; Campbell SC; Moritz T; Broderick WR; Iyer P; Arcenas AG; Van Veldhuizen PJ; Friedman N; Reda D; Warren S; Garewal H
J Urol; 2009 Nov; 182(5):2257-64. PubMed ID: 19758618
[TBL] [Abstract][Full Text] [Related]
2. Zoledronic acid initiated during the first year of androgen deprivation therapy increases bone mineral density in patients with prostate cancer.
Ryan CW; Huo D; Demers LM; Beer TM; Lacerna LV
J Urol; 2006 Sep; 176(3):972-8; discussion 978. PubMed ID: 16890673
[TBL] [Abstract][Full Text] [Related]
3. Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer.
Smith MR; Eastham J; Gleason DM; Shasha D; Tchekmedyian S; Zinner N
J Urol; 2003 Jun; 169(6):2008-12. PubMed ID: 12771706
[TBL] [Abstract][Full Text] [Related]
4. Comparative study of the protective effect of different intravenous bisphosphonates on the decrease in bone mineral density in patients submitted to radical prostatectomy undergoing androgen deprivation therapy. A prospective open-label controlled study.
Rodrigues P; Hering FO; Bruna P; Meller A; Afonso Y
Int J Urol; 2007 Apr; 14(4):317-20. PubMed ID: 17470161
[TBL] [Abstract][Full Text] [Related]
5. Lifestyle factors and duration of androgen deprivation affect bone mineral density of patients with prostate cancer during first year of therapy.
Ryan CW; Huo D; Stallings JW; Davis RL; Beer TM; McWhorter LT
Urology; 2007 Jul; 70(1):122-6. PubMed ID: 17656221
[TBL] [Abstract][Full Text] [Related]
6. The effect of zoledronic acid on bone mineral density in patients undergoing androgen deprivation therapy.
Israeli RS; Rosenberg SJ; Saltzstein DR; Gottesman JE; Goldstein HR; Hull GW; Tran DN; Warsi GM; Lacerna LV
Clin Genitourin Cancer; 2007 Mar; 5(4):271-7. PubMed ID: 17553207
[TBL] [Abstract][Full Text] [Related]
7. Single infusion of zoledronic acid to prevent androgen deprivation therapy-induced bone loss in men with hormone-naive prostate carcinoma.
Satoh T; Kimura M; Matsumoto K; Tabata K; Okusa H; Bessho H; Iwamura M; Ishiyama H; Hayakawa K; Baba S
Cancer; 2009 Aug; 115(15):3468-74. PubMed ID: 19484786
[TBL] [Abstract][Full Text] [Related]
8. Suppression of bone density loss and bone turnover in patients with hormone-sensitive prostate cancer and receiving zoledronic acid.
Ryan CW; Huo D; Bylow K; Demers LM; Stadler WM; Henderson TO; Vogelzang NJ
BJU Int; 2007 Jul; 100(1):70-5. PubMed ID: 17552955
[TBL] [Abstract][Full Text] [Related]
9. Androgen deprivation in veterans with prostate cancer: implications for skeletal health.
Wilcox A; Carnes ML; Moon TD; Tobias R; Baade H; Stamos E; Elliott ME
Ann Pharmacother; 2006 Dec; 40(12):2107-14. PubMed ID: 17132807
[TBL] [Abstract][Full Text] [Related]
10. Preventive effect of risedronate on bone loss in men receiving androgen-deprivation therapy for prostate cancer.
Ishizaka K; Machida T; Kobayashi S; Kanbe N; Kitahara S; Yoshida K
Int J Urol; 2007 Dec; 14(12):1071-5. PubMed ID: 18036042
[TBL] [Abstract][Full Text] [Related]
11. Osteoporosis in men treated with androgen deprivation therapy for prostate cancer.
Ross RW; Small EJ
J Urol; 2002 May; 167(5):1952-6. PubMed ID: 11956415
[TBL] [Abstract][Full Text] [Related]
12. The use of zoledronic acid in men receiving androgen deprivation therapy for prostate cancer with severe osteopenia or osteoporosis.
Campbell SC; Bhoopalam N; Moritz TE; Pandya M; Iyer P; Vanveldhuizen P; Ellis NK; Thottapurathu L; Garewal H; Warren SR; Friedman N; Reda DJ
Urology; 2010 May; 75(5):1138-43. PubMed ID: 20303574
[TBL] [Abstract][Full Text] [Related]
13. Long term zoledronic acid during androgen blockade for prostate cancer.
Casey R; Gesztesi Z; Rochford J
Can J Urol; 2010 Jun; 17(3):5170-7. PubMed ID: 20566009
[TBL] [Abstract][Full Text] [Related]
14. Bone health in men receiving androgen deprivation therapy for prostate cancer.
Eastham JA
J Urol; 2007 Jan; 177(1):17-24. PubMed ID: 17161994
[TBL] [Abstract][Full Text] [Related]
15. Preserving bone health in patients with hormone-sensitive prostate cancer: the role of bisphosphonates.
Saad F; Abrahamsson PA; Miller K
BJU Int; 2009 Dec; 104(11):1573-9. PubMed ID: 20053188
[TBL] [Abstract][Full Text] [Related]
16. Alendronate decreases the fracture risk in patients with prostate cancer on androgen-deprivation therapy and with severe osteopenia or osteoporosis.
Planas J; Trilla E; Raventós C; Cecchini L; Orsola A; Salvador C; Placer J; Encabo G; Morote J
BJU Int; 2009 Dec; 104(11):1637-40. PubMed ID: 19549260
[TBL] [Abstract][Full Text] [Related]
17. Frequency of zoledronic acid to prevent further bone loss in osteoporotic patients undergoing androgen deprivation therapy for prostate cancer.
Wadhwa VK; Weston R; Parr NJ
BJU Int; 2010 Apr; 105(8):1082-8. PubMed ID: 19912210
[TBL] [Abstract][Full Text] [Related]
18. Managing bone loss in men with locally advanced prostate cancer receiving androgen deprivation therapy.
Israeli RS; Ryan CW; Jung LL
J Urol; 2008 Feb; 179(2):414-23. PubMed ID: 18076933
[TBL] [Abstract][Full Text] [Related]
19. The role of bisphosphonates in men with prostate cancer receiving androgen deprivation therapy.
Smith MR
Oncology (Williston Park); 2004 May; 18(5 Suppl 3):21-5. PubMed ID: 15202584
[TBL] [Abstract][Full Text] [Related]
20. Diagnosis and management of treatment-related osteoporosis in men with prostate carcinoma.
Smith MR
Cancer; 2003 Feb; 97(3 Suppl):789-95. PubMed ID: 12548577
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
